Movatterモバイル変換


[0]ホーム

URL:


US20030113900A1 - Methods of preserving prokaryotic cells and compositions obtained thereby - Google Patents

Methods of preserving prokaryotic cells and compositions obtained thereby
Download PDF

Info

Publication number
US20030113900A1
US20030113900A1US10/215,060US21506002AUS2003113900A1US 20030113900 A1US20030113900 A1US 20030113900A1US 21506002 AUS21506002 AUS 21506002AUS 2003113900 A1US2003113900 A1US 2003113900A1
Authority
US
United States
Prior art keywords
leu
val
trehalose
glu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/215,060
Inventor
Alan Tunnacliffe
David Welsh
Bruce Roser
Kamaljit Dhaliwal
Camilo Colaco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IndividualfiledCriticalIndividual
Priority to US10/215,060priorityCriticalpatent/US20030113900A1/en
Publication of US20030113900A1publicationCriticalpatent/US20030113900A1/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

This invention provides methods of drying and stabilizing prokaryotic cells, and the compositions obtained thereby. The cells are first cultured or incubated under conditions sufficient to induce intracellular trehalose, suspended in a stabilizing solution and dried to form a solid glass. The resulting product is storage-stable at room temperature, showing little viability loss on storage.

Description

Claims (24)

We claim:
1. A method of preserving prokaryotic cells comprising the steps of:
a) increasing intracellular trehalose concentration in the prokaryotic cells to an amount effective to increase storage stability;
b) mixing the prokaryotic cells obtained in step a) with a drying solution comprising a stabilizing agent; and
c) drying the product of step b) under conditions sufficient to produce a glass form of the stabilizing agent having less than about 5% residual moisture.
2. The method according toclaim 1, wherein the method of increasing intracellular trehalose concentration is selected from the group consisting of culturing in an osmolarity sufficient to increase intracellular trehalose production, expressing a recombinant trehalose synthase gene or genes and introducing exogenous trehalose.
3. The method according toclaim 2, wherein the osmolarity is at least about 350 mOsmoles −1.5 Osmoles
4. The method according toclaim 2, wherein the osmolarity is at least about 400 mOsmoles −1 Osmole.
5. The method according toclaim 2, wherein the osmolarity is at least about 300 mOsmoles.
6. The method according toclaim 2, wherein the osmolarity is at least about 500 mOsmoles.
7. The method according toclaim 2, wherein the osmolarity is increased by adding at least one salt wherein the salt is selected from the group consisting of Na2PO4, KH2PO4, NH4Cl, NaCl, MgSO4, CaCl2, thiamine HCl, or any combination thereof.
8. The method according toclaim 1, wherein the prokaryotic cells are bacteria.
9. The method according toclaim 8, wherein the bacteria are selected from the group consisting of Escherichia, Bacillus, Salmonella, or Vibrio.
10. The method according toclaim 1, wherein the stabilizing agent is trehalose.
11. The method according toclaim 10, wherein the intracellular concentration of trehalose is at least about 100 mM.
12. The method according toclaim 1, wherein the stabilizing agent is a non-reducing carbohydrate.
13. The method according toclaim 12, wherein the drying solution comprises at least about 25% non-reducing carbohydrate.
14. The method according toclaim 12, wherein the drying solution comprises at least about 45% non-reducing carbohydrate.
15. The method according toclaim 12, wherein the non-reducing carbohydrate is selected from the group consisting of trehalose, maltitol (4-O-β-D-glucopyranosyl-D-glucitol), lactitol (4-O-β-D-galactopyranosyl-D-glucitol), palatinit [a mixture of GPS (α-D-glucopyranosyl-1→6-sorbitol) and GPM (α-D-glucopyranosyl-1→6-mannitol)], GPS, GPM and hydrogenated maltooligosaccharides and maltooligosaccharides.
16. The method according toclaim 1, wherein the drying comprises the following steps:
a) evaporating the solution to obtain a syrup;
b) exposing the syrup to a pressure reduced external pressure and temperature sufficient to cause boiling of the syrup; and
c) removing moisture so that residual moisture does not exceed about 5%.
17. The method according toclaim 16, wherein the vacuum is initially about 30 mT with an initial temperature of about 40° C.
18. The method according toclaim 1, wherein step c) further comprises the steps of i) holding the temperature at about 40° C. for about 16 hours; and ii) raising the temperature incrementally to about 80° C. at a rate of about 2.5° C. per minute at increment of about 2° C., wherein each increment is of a duration of about 12 minutes.
19. The method according toclaim 1, where the glass has a residual moisture that does not exceed about 2.5%.
20. The method according toclaim 1 wherein the glass is a foamed glass matrix.
21. A composition obtained according to the method ofclaim 1.
22. The method according toclaim 21, wherein the solvent is aqueous.
23. The method according toclaim 1, further comprising the step of: d) reconstituting the prokaryotic cells by adding a suitable solvent.
24. A method for reconstituting dried, stabilized prokaryotic cells comprising adding a suitable solvent to the dried prokaryotic cells obtained inclaim 1 in an amount sufficient to attain viability.
US10/215,0601996-12-052002-08-07Methods of preserving prokaryotic cells and compositions obtained therebyAbandonedUS20030113900A1 (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US10/215,060US20030113900A1 (en)1996-12-052002-08-07Methods of preserving prokaryotic cells and compositions obtained thereby

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US3242396P1996-12-051996-12-05
US08/985,343US6468782B1 (en)1996-12-051997-12-04Methods of preserving prokaryotic cells and compositions obtained thereby
US10/215,060US20030113900A1 (en)1996-12-052002-08-07Methods of preserving prokaryotic cells and compositions obtained thereby

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US08/985,343ContinuationUS6468782B1 (en)1996-12-051997-12-04Methods of preserving prokaryotic cells and compositions obtained thereby

Publications (1)

Publication NumberPublication Date
US20030113900A1true US20030113900A1 (en)2003-06-19

Family

ID=21864890

Family Applications (2)

Application NumberTitlePriority DateFiling Date
US08/985,343Expired - Fee RelatedUS6468782B1 (en)1996-12-051997-12-04Methods of preserving prokaryotic cells and compositions obtained thereby
US10/215,060AbandonedUS20030113900A1 (en)1996-12-052002-08-07Methods of preserving prokaryotic cells and compositions obtained thereby

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
US08/985,343Expired - Fee RelatedUS6468782B1 (en)1996-12-051997-12-04Methods of preserving prokaryotic cells and compositions obtained thereby

Country Status (10)

CountryLink
US (2)US6468782B1 (en)
EP (1)EP0946710B1 (en)
JP (1)JP2001505431A (en)
CN (1)CN1239997A (en)
AT (1)ATE309326T1 (en)
AU (1)AU721391B2 (en)
CA (1)CA2272821A1 (en)
DE (1)DE69734600T2 (en)
WO (1)WO1998024882A1 (en)
ZA (1)ZA9710974B (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20030113273A1 (en)*1996-06-172003-06-19Patton John S.Methods and compositions for pulmonary delivery of insulin
US20050276846A1 (en)*1994-12-022005-12-15Roser Bruce JSolid dose delivery vehicle and methods of making same
US20070072293A1 (en)*2005-09-262007-03-29Manoj KoleProcess for stabilization of bacterial cells
US7300919B2 (en)1992-09-292007-11-27Nektar TherapeuticsPulmonary delivery of active fragments of parathyroid hormone
US7306787B2 (en)1997-09-292007-12-11Nektar TherapeuticsEngineered particles and methods of use
US7521069B2 (en)1994-03-072009-04-21Novartis AgMethods and compositions for pulmonary delivery of insulin
US7628978B2 (en)1997-09-292009-12-08Novartis Pharma AgStabilized preparations for use in metered dose inhalers
US20100286075A1 (en)*2007-12-312010-11-11Sa-Won LeeAmphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
US8246934B2 (en)1997-09-292012-08-21Novartis AgRespiratory dispersion for metered dose inhalers comprising perforated microstructures
US8404217B2 (en)2000-05-102013-03-26Novartis AgFormulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US8709484B2 (en)2000-05-102014-04-29Novartis AgPhospholipid-based powders for drug delivery
US8715623B2 (en)2001-12-192014-05-06Novartis AgPulmonary delivery of aminoglycoside
US8877162B2 (en)2000-05-102014-11-04Novartis AgStable metal ion-lipid powdered pharmaceutical compositions for drug delivery
WO2017127399A1 (en)*2016-01-192017-07-27El-Fahmawi BassamMethod and device for maintaining mammalian and microbial cells viable and intact during ambient temperature transport and storage
US9795562B2 (en)2007-12-312017-10-24Samyang Biopharmaceuticals CorporationMethod for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6468782B1 (en)*1996-12-052002-10-22Quadrant Healthcare (Uk) LimitedMethods of preserving prokaryotic cells and compositions obtained thereby
US7569342B2 (en)1997-12-102009-08-04Sierra Molecular Corp.Removal of molecular assay interferences
GB9919732D0 (en)*1999-08-191999-10-20Colaco CamiloTrehalose producing cells as vaccines
CA2382061A1 (en)*1999-08-192001-02-22Victor BronshteinPreservation of bacterial cells at ambient temperatures
US6653062B1 (en)*2000-07-262003-11-25Wisconsin Alumni Research FoundationPreservation and storage medium for biological materials
US20040110267A1 (en)*2000-12-152004-06-10StratageneRoom temperature stable competent cells
EP1378565B1 (en)*2001-02-022006-06-07Suntory LimitedMethod of producing active dry yeast
GB0517688D0 (en)*2005-08-312005-10-05Cambridge Biostability LtdImprovements in the stabilisation of biological materials
GB2430880A (en)*2005-10-042007-04-11Cambridge Biostability LtdPharmaceutical compositions stabilized in glassy particles
GB0523638D0 (en)*2005-11-212005-12-28Cambridge Biostability LtdPharmaceutical device for the administration of substances to patients
WO2007079147A2 (en)*2005-12-282007-07-12Advanced Bionutrition CorporationA delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
US8968721B2 (en)2005-12-282015-03-03Advanced Bionutrition CorporationDelivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
JP5285617B2 (en)2006-12-182013-09-11アドバンスド バイオニュートリション コーポレーション Dry food products containing live probiotics
BRPI0811161A2 (en)*2007-05-182014-10-07Medimmune Llc CONSERVATION OF BIOACTIVE MATERIALS BY LIOFILIZED FOAM.
CA2711147A1 (en)*2008-01-032009-07-16Proterro, Inc.Transgenic photosynthetic microorganisms and photobioreactor
GB0900350D0 (en)2009-01-092009-02-11Cambridge Entpr LtdFormulations of viable bacteria for oral delivery
CA2986751A1 (en)2009-03-272010-09-30Intervet International B.V.Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
MY157343A (en)*2009-05-262016-05-31Advanced Bionutrition CorpStable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
WO2011089391A1 (en)2010-01-212011-07-28Cambridge Enterprise LimitedMammalian cell preservation methods
US9504750B2 (en)2010-01-282016-11-29Advanced Bionutrition CorporationStabilizing composition for biological materials
US8834951B2 (en)2010-01-282014-09-16Advanced Bionutrition CorporationDry glassy composition comprising a bioactive material
NZ607226A (en)2010-08-132015-03-27Advanced Bionutrition CorpDry storage stabilizing composition for biological materials
US20120222979A1 (en)2011-03-042012-09-06Elwha LLC, a limited liability company of the State of DelawareGlassy compositions
US9012185B2 (en)*2011-11-282015-04-21Pyro-E, LlcThermal cycling device with phase changing fluids
MY194231A (en)2015-07-292022-11-23Advanced Bionutrition CorpStable dry probiotic compositions for special dietary uses
US10843244B2 (en)2016-08-232020-11-24Bulldog Green Remediation, Inc.Methods for bioremediation of hydrocarbon-contaminated media
EP3839039A1 (en)*2019-12-162021-06-234D Pharma Research LimitedProviding bacterial biomass with improved storage stability
US20230082652A1 (en)*2020-02-282023-03-16Somnio Global Holdings, LlcCapillary assisted vitrification processes and materials for preservation of biological samples
CN116064360A (en)*2022-11-182023-05-05上海理工大学 A method for improving the freeze-drying survival rate of bacterial strains

Citations (25)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4436728A (en)*1982-05-261984-03-13Ribi Immunochem Research, Inc.Refined detoxified endotoxin product
US4620847A (en)*1984-06-011986-11-04Vsesojuzny Nauchno-Issledovatelsky Institut Meditsinskikh PolimerovDevice for administering powdered substances
US4684719A (en)*1984-06-051987-08-04Ss Pharmaceutical Co., Ltd.α,α-trehalose fatty acid diester derivative
US4726947A (en)*1978-03-101988-02-23Matsui Toatsu Chemicals, Inc.Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same
US4793997A (en)*1985-03-281988-12-27Standard Telephone Cables Public Ltd. Co.Controlled delivery device
US4814436A (en)*1985-12-161989-03-21Ss Pharmaceutical Co., Ltd.Derivative of α, α-trehalose and a process for preparing the same
US4855326A (en)*1987-04-201989-08-08Fuisz Pharmaceutical Ltd.Rapidly dissoluble medicinal dosage unit and method of manufacture
US4891319A (en)*1985-07-091990-01-02Quadrant Bioresources LimitedProtection of proteins and the like
US5026566A (en)*1987-06-291991-06-25Quadrant Bioresources, LimitedDried food containing trehalose and method for preparing same
US5057540A (en)*1987-05-291991-10-15Cambridge Biotech CorporationSaponin adjuvant
US5077284A (en)*1988-12-301991-12-31Loria Roger MUse of dehydroepiandrosterone to improve immune response
US5149653A (en)*1988-01-211992-09-22Quadrant Bioresources LimitedPreservation of viruses
US5171568A (en)*1984-04-061992-12-15Chiron CorporationRecombinant herpes simplex gb-gd vaccine
US5306506A (en)*1990-07-111994-04-26Eurand International S.P.A.Pharmaceutical composition for rapid suspension in water
US5380473A (en)*1992-10-231995-01-10Fuisz Technologies Ltd.Process for making shearform matrix
US5387431A (en)*1991-10-251995-02-07Fuisz Technologies Ltd.Saccharide-based matrix
US5407684A (en)*1988-12-301995-04-18Virginia Commonwealth UniversityUse of DHEA as a medicinal
US5425951A (en)*1988-05-181995-06-20Cryopharm CorporationMethod of reconstituting lyophilized cells
US5512547A (en)*1994-10-131996-04-30Wisconsin Alumni Research FoundationPharmaceutical composition of botulinum neurotoxin and method of preparation
US5567439A (en)*1994-06-141996-10-22Fuisz Technologies Ltd.Delivery of controlled-release systems(s)
US5589167A (en)*1993-02-231996-12-31Genentech, Inc.Excipient stabilization of polypeptides treated with organic solvents
US5728574A (en)*1993-07-191998-03-17Zeneca LimitedViability of bacterial dried cells
US5766520A (en)*1996-07-151998-06-16Universal Preservation Technologies, Inc.Preservation by foam formation
US5780295A (en)*1990-09-121998-07-14Life Cell CorporationApparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US6468782B1 (en)*1996-12-052002-10-22Quadrant Healthcare (Uk) LimitedMethods of preserving prokaryotic cells and compositions obtained thereby

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
DE2246013A1 (en)1972-09-201974-03-28Boehringer Mannheim Gmbh PROCESS FOR THE MANUFACTURING OF POROUS TABLETS
FR2238476A1 (en)1973-07-231975-02-21Aries RobertDouble esters of zeranol and natural hormones - and their implants for livestock, have protein anabolism props
JPS58216695A (en)1982-06-071983-12-16Otsuka Shokuhin Kogyo KkPreparation of trehalose
EP0139286B1 (en)1983-10-141991-08-21Sumitomo Pharmaceuticals Company, LimitedProlonged sustained-release preparations
GB8604983D0 (en)1986-02-281986-04-09Biocompatibles LtdProtein preservation
WO1990011756A1 (en)1989-04-121990-10-18Aberdeen UniversitySlow release vitreous systems
US5312909A (en)*1990-03-281994-05-17Gist Brocades, N.V.Recombinant DNA encoding neutral trehalase
WO1991016924A1 (en)1990-05-101991-11-14The Dana-Farber Cancer InstituteEnhancing the association of exogenous peptides with class i mhc molecules on immune system cells
GB9105992D0 (en)1991-03-211991-05-08Smithkline Beecham BiologVaccine
EP0551457B1 (en)1991-07-311995-08-09Farros Blatter AgGrinder for grinding a cylindrical or spherical surface of a roll, especially a paper machine roll
GB9125695D0 (en)1991-12-031992-01-29Mastavac LimitedMedical preparations
AU3125193A (en)1991-12-051993-06-28Pitman-Moore, Inc.A carbohydrate glass matrix for the sustained release of a therapeutic agent
NL9200844A (en)1992-05-131993-12-01De Wijdeven Gijsbertus G P Van DEVICE AND METHOD FOR INJECTING WITH A SOLID SUBSTANCE.
TW404844B (en)1993-04-082000-09-11Oxford Biosciences LtdNeedleless syringe
WO1995006126A1 (en)1993-08-241995-03-02Mogen International N.V.Production of trehalose in plants
US5565341A (en)1993-08-131996-10-15Kureha Chemical Industry Co., Ltd.Process for producing trehalose
US5955448A (en)1994-08-191999-09-21Quadrant Holdings Cambridge LimitedMethod for stabilization of biological substances during drying and subsequent storage and compositions thereof
JPH08157491A (en)1994-11-301996-06-18Hayashibara Biochem Lab IncProduction of trehalose derivative
HUP9901716A3 (en)1995-06-072000-04-28Quadrant Holdings CambridgeMethods for stably incorporating substances within dry, foamed glass matrices and compositions obtained thereby

Patent Citations (25)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US4726947A (en)*1978-03-101988-02-23Matsui Toatsu Chemicals, Inc.Bacterial cell extract, process for preparing same, antitumor preparation containing same, and adjuvant preparation containing same
US4436728A (en)*1982-05-261984-03-13Ribi Immunochem Research, Inc.Refined detoxified endotoxin product
US5171568A (en)*1984-04-061992-12-15Chiron CorporationRecombinant herpes simplex gb-gd vaccine
US4620847A (en)*1984-06-011986-11-04Vsesojuzny Nauchno-Issledovatelsky Institut Meditsinskikh PolimerovDevice for administering powdered substances
US4684719A (en)*1984-06-051987-08-04Ss Pharmaceutical Co., Ltd.α,α-trehalose fatty acid diester derivative
US4793997A (en)*1985-03-281988-12-27Standard Telephone Cables Public Ltd. Co.Controlled delivery device
US4891319A (en)*1985-07-091990-01-02Quadrant Bioresources LimitedProtection of proteins and the like
US4814436A (en)*1985-12-161989-03-21Ss Pharmaceutical Co., Ltd.Derivative of α, α-trehalose and a process for preparing the same
US4855326A (en)*1987-04-201989-08-08Fuisz Pharmaceutical Ltd.Rapidly dissoluble medicinal dosage unit and method of manufacture
US5057540A (en)*1987-05-291991-10-15Cambridge Biotech CorporationSaponin adjuvant
US5026566A (en)*1987-06-291991-06-25Quadrant Bioresources, LimitedDried food containing trehalose and method for preparing same
US5149653A (en)*1988-01-211992-09-22Quadrant Bioresources LimitedPreservation of viruses
US5425951A (en)*1988-05-181995-06-20Cryopharm CorporationMethod of reconstituting lyophilized cells
US5407684A (en)*1988-12-301995-04-18Virginia Commonwealth UniversityUse of DHEA as a medicinal
US5077284A (en)*1988-12-301991-12-31Loria Roger MUse of dehydroepiandrosterone to improve immune response
US5306506A (en)*1990-07-111994-04-26Eurand International S.P.A.Pharmaceutical composition for rapid suspension in water
US5780295A (en)*1990-09-121998-07-14Life Cell CorporationApparatus for cryopreparation, dry stabilization and rehydration of biological suspensions
US5387431A (en)*1991-10-251995-02-07Fuisz Technologies Ltd.Saccharide-based matrix
US5380473A (en)*1992-10-231995-01-10Fuisz Technologies Ltd.Process for making shearform matrix
US5589167A (en)*1993-02-231996-12-31Genentech, Inc.Excipient stabilization of polypeptides treated with organic solvents
US5728574A (en)*1993-07-191998-03-17Zeneca LimitedViability of bacterial dried cells
US5567439A (en)*1994-06-141996-10-22Fuisz Technologies Ltd.Delivery of controlled-release systems(s)
US5512547A (en)*1994-10-131996-04-30Wisconsin Alumni Research FoundationPharmaceutical composition of botulinum neurotoxin and method of preparation
US5766520A (en)*1996-07-151998-06-16Universal Preservation Technologies, Inc.Preservation by foam formation
US6468782B1 (en)*1996-12-052002-10-22Quadrant Healthcare (Uk) LimitedMethods of preserving prokaryotic cells and compositions obtained thereby

Cited By (25)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20080075782A1 (en)*1992-09-292008-03-27Patton John SPulmonary delivery of active fragments parathyroid hormone
US7300919B2 (en)1992-09-292007-11-27Nektar TherapeuticsPulmonary delivery of active fragments of parathyroid hormone
US20090203576A1 (en)*1994-03-072009-08-13Patton John SMethods and compositons for pulmonary delivery of insulin
US7521069B2 (en)1994-03-072009-04-21Novartis AgMethods and compositions for pulmonary delivery of insulin
US7785631B2 (en)1994-12-022010-08-31Quadrant Drug Delivery LimitedSolid dose delivery vehicle and methods of making same
US20050276846A1 (en)*1994-12-022005-12-15Roser Bruce JSolid dose delivery vehicle and methods of making same
US7744925B2 (en)1994-12-022010-06-29Quadrant Drug Delivery LimitedSolid dose delivery vehicle and methods of making same
US7780991B2 (en)1994-12-022010-08-24Quadrant Drug Delivery LimitedSolid dose delivery vehicle and methods of making same
US20030113273A1 (en)*1996-06-172003-06-19Patton John S.Methods and compositions for pulmonary delivery of insulin
US8246934B2 (en)1997-09-292012-08-21Novartis AgRespiratory dispersion for metered dose inhalers comprising perforated microstructures
US9554993B2 (en)1997-09-292017-01-31Novartis AgPulmonary delivery particles comprising an active agent
US7306787B2 (en)1997-09-292007-12-11Nektar TherapeuticsEngineered particles and methods of use
US7628978B2 (en)1997-09-292009-12-08Novartis Pharma AgStabilized preparations for use in metered dose inhalers
US8404217B2 (en)2000-05-102013-03-26Novartis AgFormulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US8709484B2 (en)2000-05-102014-04-29Novartis AgPhospholipid-based powders for drug delivery
US8877162B2 (en)2000-05-102014-11-04Novartis AgStable metal ion-lipid powdered pharmaceutical compositions for drug delivery
US9439862B2 (en)2000-05-102016-09-13Novartis AgPhospholipid-based powders for drug delivery
US8715623B2 (en)2001-12-192014-05-06Novartis AgPulmonary delivery of aminoglycoside
US9421166B2 (en)2001-12-192016-08-23Novartis AgPulmonary delivery of aminoglycoside
WO2007038420A3 (en)*2005-09-262009-04-23Aeras Global Tb Vaccine FoundProcess for stabilization of bacterial cells
US20070072293A1 (en)*2005-09-262007-03-29Manoj KoleProcess for stabilization of bacterial cells
US20100286075A1 (en)*2007-12-312010-11-11Sa-Won LeeAmphiphilic block copolymer micelle composition containing taxane and manufacturing process of the same
US9795562B2 (en)2007-12-312017-10-24Samyang Biopharmaceuticals CorporationMethod for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
US9801818B2 (en)2007-12-312017-10-31Samyang Biopharmaceuticals CorporationMethod for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
WO2017127399A1 (en)*2016-01-192017-07-27El-Fahmawi BassamMethod and device for maintaining mammalian and microbial cells viable and intact during ambient temperature transport and storage

Also Published As

Publication numberPublication date
AU721391B2 (en)2000-06-29
DE69734600D1 (en)2005-12-15
JP2001505431A (en)2001-04-24
US6468782B1 (en)2002-10-22
CN1239997A (en)1999-12-29
ATE309326T1 (en)2005-11-15
ZA9710974B (en)1998-12-28
EP0946710A1 (en)1999-10-06
AU5403498A (en)1998-06-29
WO1998024882A1 (en)1998-06-11
DE69734600T2 (en)2006-07-20
CA2272821A1 (en)1998-06-11
EP0946710B1 (en)2005-11-09

Similar Documents

PublicationPublication DateTitle
US6468782B1 (en)Methods of preserving prokaryotic cells and compositions obtained thereby
US6503411B1 (en)Stable compositions
US8329447B2 (en)Strain of Lactobacillus crispatus
Passot et al.Critical water activity and amorphous state for optimal preservation of lyophilised lactic acid bacteria
US9469835B2 (en)Preservation by vaporization
Schoug et al.Freeze-drying of Lactobacillus coryniformis Si3—effects of sucrose concentration, cell density, and freezing rate on cell survival and thermophysical properties
US7153472B1 (en)Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
Ohtake et al.Formulation and stabilization of Francisella tularensis live vaccine strain
US20110064723A1 (en)Formulation for room temperature stabilization of a live attenuated bacterial vaccine
CA3068958A1 (en)High potency stable formulations of vaginal lactobacillus
EP4077632A1 (en)Providing bacterial biomass with improved storage stability
WO2001037804A2 (en)Preservation and formulation of bioactive materials
US20210040436A1 (en)Process for lyophilizing a microorganism
Bullifent et al.Stabilisation of Salmonella vaccine vectors by the induction of trehalose biosynthesis
Tan et al.Effect of disaccharide-polyol systems on the thermal stability of freeze-dried Mycobacterium bovis
US20070243200A1 (en)Trehalose producing cells as vaccines
AU2021325149A1 (en)Lyophilized live bordetella vaccines
Maister et al.Survival during storage of Serratia marcescens dried by continuous vacuum sublimation
LindersDrying of Lactobacillus plantarum
SU721488A1 (en)Streptococcus diacetilactis aroma-producing lactic streptococci strain employed in bacterial preparate for cheeses with low second heating temperature

Legal Events

DateCodeTitleDescription
STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION


[8]ページ先頭

©2009-2025 Movatter.jp